Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

Phase 3

• Conditions: Portal Vein Thrombosis
• Interventions: Drug: rivaroxaban

• Registration Number: NCT03193502
• Lead Sponsor: Sherief Abd-Elsalam

Brief Summary

-Rivaroxaban is factor Xa inhibitor

Detailed Description

PVT is a common complication of liver cirrhosis

Study Timeline

• Study Start: 2014-05-01
• Study First Submitted: 2017-06-17
• Study First Submitted QC: 2017-06-17
• Study First Posted: 2017-06-20
• Status Verified: 2017-10
• Last Update Submitted: 2017-10-12
• Last Update Posted: 2017-10-13
• Primary Completion: 2020-07
• Study Completion: 2020-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Acute PVT

Exclusion Criteria

• Malignant PVT
• Bleeding disorders

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Portal Vein thrombosis	rivaroxaban	rivaroxaban

Primary Outcome Measures

Name	Time	Method
Number of patients with recanalized portal vein	6 months	recanalization of portal vein

Trial Locations

Locations (1)

Tropical medicine dept.-Tanta university hospital; 🇪🇬 Cairo, Egypt